Landmark Support for Pharmacist-Prescribed Buprenorphine in Minnesota
In a major win for low-barrier access to Medications for Opioid Use Disorder (MOUD), the Minnesota Medical Association (MMA) Board of Trustees recently voted unanimously to support legislative efforts that would allow appropriately trained pharmacists to independently initiate, prescribe, and administer buprenorphine.
Currently, pharmacists in Minnesota can only provide buprenorphine through a Collaborative Practice Agreement (CPA) with a physician. However, many physicians have been reluctant to sign these agreements due to liability concerns and administrative burden. By moving toward independent prescribing authority rather than a rigid statewide protocol, pharmacists gain the flexibility to adapt to the latest evidence-based practices in real time.
How this improves access in Minnesota:
Closing Rural Gaps: In many underserved and rural areas of Minnesota, pharmacies are far more accessible than specialized addiction clinics. This change turns the local pharmacy into a critical entry point for care.
Removing Administrative Barriers: Decoupling pharmacist authority from physician contracts (CPAs) removes the "red tape" that currently prevents many pharmacists from practicing at the top of their license.
Low-Barrier Initiation: By allowing pharmacists to initiate treatment, patients can start their recovery journey immediately at the point of care, reducing the risk of overdose during the wait for a traditional doctor's appointment.
At PharmacyBridge.org, we know that pharmacists are the most accessible healthcare providers. This support from the MMA is a vital step toward a future where MOUD is treated like any other essential medication.
